Towards quantum computing for clinical trial design and optimization: A perspective on new opportunities and challenges
Hakan Doğa, Sahin, M. Emre, Joao H. Bettencourt‐Silva, Pham, Anh, Eunyoung Kim, Alan Andress, Sudhir Saxena, Aritra Bose, Laxmi Parida, Jan Lukas Robertus, Kawaguchi, Hideaki, Radwa Soliman, Daniel J Blankenberg
Clinical trials are pivotal in the drug discovery process to determine the safety and efficacy of a drug candidate. The high failure rates of these trials are attributed to deficiencies in clinical model development and protocol design. Improvements in the clinical drug design process could therefore yield significant benefits for all stakeholders involved. This paper examines the current challenges faced in clinical trial design and optimization, reviews established classical computational approaches, and introduces quantum algorithms aimed at enhancing these processes. Specifically, the focus is on three critical aspects: clinical trial simulations, site selection, and cohort identification. This study aims to provide a comprehensive framework that leverages quantum computing to innovate and refine the efficiency and effectiveness of clinical trials.
Clinical trials are pivotal in the drug discovery process to determine the safety and efficacy of a drug candidate. The high failure rates of these trials are attributed to deficiencies in clinical model development and protocol design. Improvements in the clinical drug design process could therefore yield significant benefits for all stakeholders involved. This paper examines the current challenges faced in clinical trial design and optimization, reviews established classical computational approaches, and introduces quantum algorithms aimed at enhancing these processes. Specifically, the focus is on three critical aspects: clinical trial simulations, site selection, and cohort identification. This study aims to provide a comprehensive framework that leverages quantum computing to innovate and refine the efficiency and effectiveness of clinical trials.
Clinical trials represent one of the most resource-intensive and time-consuming phases of drug development, often constrained by complex patient stratification, high attrition rates, and logistical inefficiencies. Recent advances in quantum computing introduce new computational paradigms capable of addressing combinatorial optimization, probabilistic modeling, and high-dimensional data analysis challenges inherent in clinical research. This paper examines clinical trial optimization via quantum computing, exploring how quantum algorithms and hybrid quantum–classical frameworks can enhance patient recruitment, adaptive trial design, biomarker discovery, and outcome prediction. By synthesizing developments in quantum optimization, machine learning, and biomedical data analytics, the study evaluates the feasibility and potential impact of quantum-enabled methodologies in accelerating drug development pipelines. The findings suggest that quantum computing, when strategically integrated with classical infrastructures, may reduce development timelines, improve decision accuracy, and support more personalized and efficient clinical trial processes.
Clinical trials are necessary for assessing the safety and efficacy of treatments. However, trial timelines are severely delayed with minimal success due to a multitude of factors, including imperfect trial site selection, cohort recruitment challenges, lack of efficacy, absence of reliable biomarkers, etc. Each of these factors possesses a unique computational challenge, such as data management, trial simulations, statistical analyses, and trial optimization. Recent advancements in quantum computing offer a promising opportunity to overcome these hurdles. In this opinion we uniquely explore the application of quantum optimization and quantum machine learning (QML) to the design and execution of clinical trials. We examine the current capabilities and limitations of quantum computing and outline its potential to streamline clinical trials.
Drug discovery and development is a highly complex and costly endeavor, typically requiring over a decade and substantial financial investment to bring a new drug to market. Traditional computer-aided drug design (CADD) has made significant progress in accelerating this process, but the development of quantum computing offers potential due to its unique capabilities. This paper discusses the integration of quantum computing into drug discovery and development, focusing on how quantum technologies might accelerate and enhance various stages of the drug development cycle. Specifically, we explore the application of quantum computing in addressing challenges related to drug discovery, such as molecular simulation and the prediction of drug-target interactions, as well as the optimization of clinical trial outcomes. By leveraging the inherent capabilities of quantum computing, we might be able to reduce the time and cost associated with bringing new drugs to market, ultimately benefiting public health.
Drug discovery is lengthy and expensive, with traditional computer-aided design facing limits. This paper examines integrating quantum computing across the drug development cycle to accelerate and enhance workflows and rigorous decision-making. It highlights quantum approaches for molecular simulation, drug-target interaction prediction, and optimizing clinical trials. Leveraging quantum capabilities could accelerate timelines and costs for bringing therapies to market, improving efficiency and ultimately benefiting public health.
Drug development remains a complex, time-intensive, and costly process, with high failure rates in clinical trials. The advent of quantum computing presents promising opportunities to transform pharmaceutical research and development through enhanced molecular simulations and structure-based drug design. Quantum computing uses quantum mechanical phenomena like superposition and entanglement to process complex molecular interactions more efficiently than classical computers. The integration of quantum computing with machine learning algorithms has enabled more accurate predictions of drug-target interactions and improved virtual screening of compound libraries. Applications include structure-based drug design, molecular docking, lead optimization, and drug repurposing. Notable progress has been made through collaborations between pharmaceutical companies and quantum computing firms, demonstrating practical implementations in drug discovery workflows. However, several challenges persist, including hardware limitations, algorithmic maturity, skilled workforce gaps, and regulatory considerations. The combination of quantum computing with classical computing and machine learning approaches offers a hybrid framework that maximizes the strengths of each technology. As quantum computing technology advances, it is positioned to significantly impact pharmaceutical research and development, potentially reducing development timelines and improving success rates in drug discovery. This review explains the principles, current applications, integration, and limitations of quantum computing in drug development
Research Problem: The traditional methods of drug discovery are time-consuming, costly, and at times ineffective. There is a need for more novel approaches that can enhance the processes of discovering new drugs and developing them into usable products. Objective of the Paper: This paper aims to conduct a review of the literature and find how the application of quantum computing can change the way drugs are discovered and processed in practice. Process of Review: The review process involved a comprehensive examination of the available literature and recent advances in the application of quantum computing to drug discovery. The review encompassed major studies, theories, and case studies related to the subject matter, aiming to identify the current state and potential future directions of the domain. Insights of the Review: 1. Primary Building Blocks: With quantum computing, superposition, entanglement, and other principles can be utilised to enable complex computations to be performed at higher speeds using less time than traditional computers. 2. Quantum modelling: Quantum computers are expected to accurately model the interactions of various molecules, which could result in the identification of viable drug candidates. 3. Drug Discovery Processes: Quantum algorithms are capable of faster processing than traditional methods when it comes to solving optimisation problems, such as protein structure prediction and molecular docking, in drug design. 4. Limitations and Challenges: As great as the promise of quantum computing is, it has its limitations and challenges, including hardware limitations, error rates, and the need for specialised algorithms. 5. Future Developments: The ongoing development of quantum hardware and algorithms is expected to enhance the practical applications of quantum computing in drug discovery, enabling the quicker and more cost-effective creation of new drugs.